CXCR2 and neoplasm: When we combined PI16/2 with anti-PD1 and CXCR2 blockade with SB225002, tumor control (Fig. 8B, D) and survival (Fig. 8C) were further improved compared with control group (median survivals: control 23 days, PI16/2 + anti-PD1 42 days, PI16/2 + anti-PD1 + SB225002: not reached as more than 50% complete responses), suggesting that the CXCR2-recruited cells exerted immunosuppressive activities.